Technical Analysis for ACHN - Achillion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 3.69 -3.91% -0.15
ACHN closed down 3.91 percent on Wednesday, April 18, 2018, on 39 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Earnings due: May 3

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ACHN trend table...

Date Alert Name Type % Chg
Apr 18 Downside 200 DMA Break Bearish 0.00%
Apr 18 Inside Day Range Contraction 0.00%
Apr 17 MACD Bullish Centerline Cross Bullish -3.91%
Apr 17 Upside 200 DMA Break Bullish -3.91%
Apr 17 180 Bullish Setup Bullish Swing Setup -3.91%
Apr 17 Wide Bands Range Expansion -3.91%
Apr 17 Overbought Stochastic Strength -3.91%
Apr 16 MACD Bearish Centerline Cross Bearish 3.65%
Apr 16 Wide Bands Range Expansion 3.65%
Apr 13 MACD Bullish Centerline Cross Bullish 0.27%

Older signals for ACHN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C viral (HCV) infection. The company's drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3 protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; and ACH-2684, a NS3 protease inhibitor, which has completed Phase Ia and 1b clinical trials. Its pipeline of antibacterial product candidates includes ACH-702 for the treatment of dermatologic and ophthalmic infections; and ACH-2881 for the treatment of serious resistant bacterial infections, including methicillin-resistant staphylococcus aureus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Is ACHN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.66
52 Week Low 2.58
Average Volume 2,038,227
200-Day Moving Average 3.7747
50-Day Moving Average 3.5273
20-Day Moving Average 3.6795
10-Day Moving Average 3.616
Average True Range 0.1679
ADX 14.34
+DI 23.5
-DI 18.38
Chandelier Exit (Long, 3 ATRs ) 3.5563
Chandelier Exit (Short, 3 ATRs ) 3.9137
Upper Bollinger Band 3.991
Lower Bollinger Band 3.368
Percent B (%b) 0.52
BandWidth 16.931648
MACD Line 0.0157
MACD Signal Line 0.0187
MACD Histogram -0.0029
Fundamentals Value
Market Cap 504.65 Million
Num Shares 137 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -7.38
Price-to-Sales 33.83
Price-to-Book 1.40
PEG Ratio -0.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.93
Resistance 3 (R3) 3.95 3.89 3.89
Resistance 2 (R2) 3.89 3.83 3.88 3.88
Resistance 1 (R1) 3.79 3.79 3.76 3.77 3.86
Pivot Point 3.73 3.73 3.72 3.72 3.73
Support 1 (S1) 3.63 3.67 3.60 3.61 3.52
Support 2 (S2) 3.57 3.63 3.56 3.50
Support 3 (S3) 3.47 3.57 3.49
Support 4 (S4) 3.45